'We have had a number of breakthroughs and we will continue to work on them'
’s Sunday with Laura Kuenssberg. They co-founded BioNTech in Mainz, Germany in 2008 and worked to pioneer cancer immunotherapies which can be tailored to individual patients.
While conventional vaccines are produced using weakened forms of a virus, mRNAs use only a virus’s genetic code. Asked when cancer vaccines might be accessed by many patients around the world, Prof Sahin said it could happen “before 2030”.Prof Tureci told Kuenssberg: “What we have developed over decades for cancer vaccine development has been the tailwind for developing the Covid-19 vaccine, and now the Covid-19 vaccine and our experience in developing it gives back to our cancer work.
Vi har opsummeret denne nyhed, så du kan læse den hurtigt. Hvis du er interesseret i nyheden, kan du læse hele teksten her. Læs mere: